Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Apr;64(4):544-546.
doi: 10.1016/j.jadohealth.2018.10.296. Epub 2019 Jan 4.

Bicalutamide as an Androgen Blocker With Secondary Effect of Promoting Feminization in Male-to-Female Transgender Adolescents

Anna Neyman  1 , John S Fuqua  2 , Erica A Eugster  2
Affiliations

Bicalutamide as an Androgen Blocker With Secondary Effect of Promoting Feminization in Male-to-Female Transgender Adolescents

Anna Neyman et al. J Adolesc Health. 2019 Apr.

Abstract

Purpose: The purpose of the study was to describe the novel use of bicalutamide in transgender youth.

Methods: This is a retrospective review of patients with gender dysphoria followed in the pediatric endocrine clinic at Riley Hospital for Children.

Results: Of 104 patients with gender dysphoria, 23 male-to-female adolescents received bicalutamide 50 mg daily as a second-line puberty blocker after insurance company denial of a gonadotropin-releasing hormone analog. Six patients received estrogen concurrently. Of 13 patients treated exclusively with bicalutamide seen in follow-up, 84.6% had breast development within 6 months, the majority being ≥ Tanner stage III.

Conclusions: Bicalutamide may be an alternative to gonadotropin-releasing hormone analogs in transgender male-to-female youth who are also ready to undergo physical transition.

Keywords: Bicalutamide; Gender dysphoria; Puberty blocker; Transgender care.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: The authors have no conflicts of interest to disclose.

References

    1. Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine treatment of gender-dysphoric/gender-incongruent Persons: An Endocrine Society Clinical Practice Guideline (vol 102, pg 3869, 2017). J Clin Endocr Metab 2018; 103:699. - PubMed
    1. Lawlis SM, Donkin HR, Bates JR, et al. Health Concerns of transgender and gender nonconforming youth and their parents upon presentation to a transgender clinic. J Adolesc Health 2017;61:642–8. - PubMed
    1. Prior JC, Vigna YM, Watson D. Spironolactone with physiological female steroids for presurgical therapy of male-to-female transsexualism. Arch Sex Behav 1989;18:49–57. - PubMed
    1. Reiter EO, Mauras N, McCormick K, et al. Bicalutamide plus anastrozole for the treatment of gonadotropin-independent precocious puberty in boys with testotoxicosis: A phase II, open-label pilot study (BATT). J Pediatr Endocrinol Metab 2010;23:999–1009. - PubMed
    1. Tessaris D, Matarazzo P, Mussa A, et al. Combined treatment with bicalutamide and anastrozole in a young boy with peripheral precocious puberty due to McCune-Albright Syndrome. Endocr J 2012;59:111–7. - PubMed

Publication types